Avaxia Biologics is now operating as a subsiduary of Circle33. Avaxia Biologics had been developing an anti-tumour necrosis factor (TNF) antibody for inflammatory bowel disease and UK-based VH Squared, which has an early-stage programme ongoing looking at using single-chain antibodies in GI infections and immune-mediated diseases. The firm is a clinical-stage biotechnology company working in the growing field of gut-targeted therapeutics - orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. Avaxia's proprietary oral antibody platform makes direct delivery of antibodies to the GI tract possible by overcoming some of the traditional limitations of antibody therapeutics. Avaxia's lead clinical candidate, AVX-470, is an oral anti-TNF antibody in Phase I for inflammatory bowel disease. The firm's products are bovine polyclonal antibodies, isolated from the early milk of immunized cows. Nature has designed these antibodies to be both stable to gastric digestion and safe for oral consumption. Avaxia has built a proprietary technology platform on this natural source of antibodies. The platform offers unique advantages in product safety, cost and convenience. Just as importantly, the company offers more rapid clinical development at a greatly reduced cost. Avaxia is using our platform technology to develop medication to treat serious diseases, many of them currently untreated by existing technologies. Avaxia's lead product is designed to treat oral mucositis, the painful inflammation and ulceration in the mouth caused by cancer chemotherapy and radiation therapy. All indications are that all patents,technology and assets of the firm were acquired by Circle33 LLC.- a firm formed n 2016, based in Lexington MA that through its subsidiaries engages in the development of oral antibody therapeutics for the gastrointestinal diseases.
